Pharma News - Chemdiv

Ketamine therapy swiftly reduces depression and suicidal thoughts

Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence.

CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has received a positive re...

Sanofi to buy cancer immunotherapy biotech for $1B

Sanofi will pay $1 billion to acquire privately held Amunix Pharmaceuticals and its cancer immunotherapy technology in a deal announced Tuesday by the French pharmaceutical company. ...

Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease

Vivoryon Therapeutics N.V., a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, tod...

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention

Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pou...

Omicron sweeps across nation, now 73% of new US COVID cases

Omicron has raced ahead of other variants and is now the dominant version of the coronavirus in the U.S., accounting for 73% of new infections last week, federal health officials said Monday. ...

Biogen cuts the price tag on its Alzheimer’s drug in half

Biogen is slashing the price of its Alzheimer’s treatment in half months after it debuted to widespread criticism for an initial cost that could reach $56,000 annually. ...

Relief for AZ, Amgen as FDA okays severe asthma hope tezepelumab

The FDA has approved AstraZeneca and Amgen’s severe asthma hope tezepelumab, exonerating the drugmakers’ decision to press ahead with a regulatory filing despite a failed phase 3 trial. ...

Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisors

The EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying it was unconvinced by the data submitted for the drug. ...

Novavax's COVID vaccine becomes the fifth jab to be approved for use in the EU

It was given the green light by the bloc's drugs regulator, the European Medicines Agency (EMA), on Monday.

Xalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee

Xalud Therapeutics, a clinical-stage biotechnology company developing DNA delivery therapies using a non-viral platform, announced today that the United States Food and Drug Administration (FDA) ha...

Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic Hyperplasia

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, announced today that the U.S. Food and D...